Notes to editor
This press release accompanies a presentation at ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow European Society of Cardiology News on LinkedIn
The hashtag for ESC Congress 2025 is #ESCCongress
Journalists are invited to become accredited and register here.
Check out the ESC Media and Embargo Policy.
Funding: The study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and Bayer AG.
Disclosures: Professor Butler has received consulting fees from Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, Cardiorem, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronic, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor and Zoll; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novartis, Boehringer Ingelheim-Lilly, AstraZeneca, Impulse Dynamics and Vifor.
References and notes:
1‘VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure and VICTORIA: Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction’ presented during HOT LINE 2 on 30 August 2025 at 08:43 to 08:53 in Madrid (Main Auditorium).
2Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883–1893.
3‘VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure’ presented during HOT LINE 2 on 30 August 2025 at 08:33 to 08:43 in Madrid (Main Auditorium).
4Ezekowitz JA, O’Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: Vericiguat Heart Failure with Reduced Ejection Fraction Study. JACC Heart Fail 2020;8: 931–939.
About ESC Congress 2025
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.